Kornimate/medical-research-clean huggingface dataset:
how to reduce dry needling pain in treatment of trigger points of muscle triceps sural in ankle post fracture patients

Conditions: Physical Therapy Modalities; Pain Measurement; Trigger Point Pain, Myofascial; Ankle Fractures; Rehabilitation; Needles

Summary: ankle fractures are one of the main causes of hospitalization due to injuries in chile, which also have a discharge and partial load time of approximately 12 weeks in the recovery process. this generates disuse and atrophy of the posterior musculature of the leg called the triceps sural, which makes it difficult to restart and perform the gait. we conducted this research because practically all patients with this type of diagnosis have trigger points in these muscles, and dry needling technique is one of the best for its treatment, but has the disadvantage that it produces post dry needling pain of 48 hours and there is not enough information, or consensus on which method is better to reduce post dry needling pain. this study aims to prove wich technique is most useful in reducing pain post dry needling for the treatment of trigger points in the triceps sural muscle in ankle post fracture patients.


Eligibility criteria:
inclusion criteria: * ages between 18 and 60 years of age. * man or woman. * at least one trigger point, active or latent, in the triceps sural muscle of the fractured ankle. * perform full load without using technical aids. exclusion criteria: * use of analgesics. * insurmountable fear of needles. * immune disease. * clotting disorders. * sensory disorders. * psychiatric / psychological illness. * cancer. * rheumatic diseases.

Keywords: humans excercise therapy hot temperature post dry needling range of motion, articular muscle strength
investigation of the change of vision-related quality of life in subjects treated with aflibercept according to eu label for dme.

Conditions: Macular Edema

Summary: to evaluate the change in quality of life (nei vfq 25) in subjects with dme during the first year of treatment with aflibercept according to the eu label.


Eligibility criteria:
inclusion criteria: * type 1 or 2 diabetes mellitus * diagnosis of dme secondary to diabetes mellitus involving the center of the macula (defined as the area of the center subfield on oct) in the study eye * decrease in vision determined to be primarily the result of dme in the study eye * bcva in the study eye of etdrs letter score 73 to 24 (this corresponds to a snellen equivalent of approximately 20/40 to 20/320.) exclusion criteria: * pregnancy and lactation * mismatch with inclusion criteria

Keywords: diabetic macular edema intravitreal injection
bendamustine plus rituximab (br) for relapsed or progressive marginal zone b-cell lymphoma (mzbcl)

Conditions: Marginal Zone B-cell Lymphoma

Summary: this study will be conducted to evaluate the efficacy of bendamustine plus rituximab (br) in patients with relapsed or progressive marginal zone b-cell lymphoma (mzbcl).

multi-center trial, phase ii, non-randomized, open-label, single-arm study with combined therapy of bendamustine and rituximab in patients with mzbcl who has relapsed or progressive to prior chemotherapy or chemo-radiotherapy.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed cd20-positive nodal or extranodal mzbcl 2. mzbcl patients who relapsed or progressed: * at least one and a maximum of four prior lines of chemotherapy * during or after the last chemotherapy or radiotherapy or * without progression within 6 months of the last dose of rituximab-based regimen 3. patients age ≥ 18 years 4. ecog ps 0-2 5. at least one bidimensionally measurable disease 6. adequate hematologic, renal, and hepatic functions 7. women of child-bearing potential should use two appropriate methods of contraception during the study 8. written informed consent exclusion criteria: 1. not all of the above inclusion criteria are met. 2. prior chemotherapy within 4 weeks or radiotherapy within 6 weeks 3. corticosteroids during last 28 days except chronic administration of prednisolone at a dose of \< 20mg/day for indications other than lymphomas 4. evidence of cns involvement by lymphomas 5. active hbv/hcv infections, known hiv infection 6. prior diagnosis of cancers within 5 years, except cervical intraepithelial neoplasia type 1, localized non-melanoma skin cancer, or small differentiated thyroid cancer 7. serious concurrent disease: 8. patients who are pregnant or lactating

Keywords: marginal zone b-cell lymphoma bendamustine plus rituximab
fluorescence imaging in sentinel lymph node biopsy for breast cancer and melanoma

Conditions: Breast Cancer; Cancer of Breast; Cancer of the Breast; Melanoma; Malignant Melanoma

Summary: the nir light source of our device is based on light-emitting diodes (leds), which can deliver sufficient light to biological tissues and induce fluorescence emission to meet the needs of the planned clinical studies. it should be noted that the light source is still well under the us fda recommended limit for nir exposure and ansi standard. in addition, the light source is not laser-based, which is significantly safer than other optical imaging systems utilizing laser technologies. the fluorescence signals will be received by the detector portion of our device. gain-settings could be easily adjusted during operation to optimize the contrast between high fluorescence areas (tumors) and low fluorescence areas (normal tissues). real-time fluorescence video will be displayed in the goggle eyepiece as well as on a secondary monitor to facilitate viewing by other surgeons in the room.


Eligibility criteria:
inclusion criteria: * newly diagnosed with clinically node-negative breast cancer or melanoma being staged with sln biopsy. * negative nodal basin clinical exam. * at least 18 years of age. * able to understand and willing to sign a written informed consent document. exclusion criteria: * contraindications for surgery. * receiving any investigational agents. * history of allergic reactions attributed to icg or other agents used in the study, including known iodide or seafood allergy. * presence of uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of the breast and/or axilla, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * pregnant. * breastfeeding. patients who are breastfeeding are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with icg dye.
radiation-induced cytokine cascades and their correlation with central nervous system injury

Conditions: Brain Neoplasm

Summary: treatment for brain cancer may include radiation therapy. radiation therapy is the treatment of tumors with x-rays. this study is related to understanding the side effects of radiation treatment for brain tumors. this study is being conducted by the university of rochester cancer center to compare the extent of side effects of brain cancer treatment with changes in levels of blood proteins called cytokines.


Eligibility criteria:
inclusion criteria: * any patient who will be treated to the brain or spinal axis for a cns tum patients so treated will be stratified according to whether or not the hypo is included in the treatment fields. * patients receiving external beam radiation to the brain may also be rece chemotherapy or interferon-beta. (add. #1, 11-9-95) * patients receiving high dose rate (stereotactic radiosurgery) are eligible. * patients must sign a study specific informed consent meeting all federal a guidelines. * patients of any age, including children, are eligible (add. #3, 11/25/97). exclusion criteria: * patients who have a malignancy involving the hypothalamic-pituitary ax * patients who are not treated with irradiation to the brain or spinal axis.
effectiveness of outpatient intravenous diuretic therapy for treatment of worsening heart failure (outpatient-whf)

Conditions: Heart Failure

Summary: the purpose of the outpatient-whf study is to characterize the effectiveness of outpatient intravenous diuretic therapy as a treatment for worsening heart failure.

the purpose of this study is to determine whether treating certain patients with worsening heart failure as an outpatient with intravenous and oral medications can work just as well as treating patients in the hospital. participants who enter into the study and meet eligibility criteria will be randomly chosen to either get intravenous diuretic like lasix in the clinic and get outpatient care, versus directly admitted to the hospital to receive intravenous diuretic and normal hospital care.

Eligibility criteria:
inclusion criteria: 1. ≥18 years of age 2. presentation to a duke outpatient clinic with heart failure requiring iv diuretics, as per clinician judgement 3. able to provide signed informed consent 4. successful completion of euroqol-5 dimensions survey exclusion criteria: 1. managing clinician without equipoise for initial outpatient treatment strategy versus initial hospitalization-based treatment strategy for heart failure, and decline to accept randomization. 2. patient without equipoise for initial outpatient treatment strategy versus initial hospitalization-based treatment strategy for heart failure, and decline to accept randomization. 3. history of left ventricular assist device or heart transplantation 4. end-stage kidney disease requiring chronic dialysis therapy 5. new diagnosis of heart failure 6. pregnant or breast-feeding 7. fever \>101.0 degrees fahrenheit at screening 8. any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol
the leukemia and lymphoma society (lls) national research registry

Conditions: Blood Cancer

Summary: the leukemia and lymphoma society (lls) has built a national research registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.

the lls national research registry is a real-world experiences and outcomes research registry; a collection of patient information and medical data, over time, about people who have a particular disease or condition, or who receive a particular treatment. the lls national research registry protocol will: 1. answer research questions using data collected from people with blood cancers. such research involves analyses of subject profile information completed by subjects and medical records data. 2. obtain permission from lls national research registry research subjects to have ciitizen, a third-party engaged by lls, act as their proxy to retrieve full medical record data including images at no cost to research subjects. note: patient can choose to upload their medical records into their account, directly. 3. obtain permission from lls national research registry research subjects to share summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. "summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed. 4. obtain permission from lls national research registry research subjects to be contacted from time to time, for them to provide updated medical information.

Eligibility criteria:
inclusion criteria: people with blood cancer, before, during, and after blood cancer treatments. exclusion criteria: people unable or unwilling to sign informed consent.
analyze changes in respiratory rate when using the scare respirator

Conditions: Apnea of Newborn; Preterm Labor

Summary: pilot study of 10 preterm, who are going to be randomly placed to 3 phases : 2 hour of basal observation of respiratory rate, heart rate, saturation, nips and aeeg recording, 2 hours with a 20cycles/minute with "scare ventilator", and 2 hours of 40 cycles/minute with "scare ventilator"

with this pilot study the investigator's want to see if the "scare respirator" can modify the vital signs of the newborn (nb) and if there is a relationship according to the frequency per minute given by the scare respirator and the patient's respiratory rate. the "scare respirator" has been used many times to prevent central apnea in the newborn. this involves using a mechanical ventilator, but instead of connecting it to the patient's trachea to inflate his lungs, the air flow is connected to a surgical glove that inflates and deflates, with the optimal respiratory rate that the patient should have. this will be placed on the back to stimulate it tactically giving the necessary impulse of inspiration so that the patient alone can acquire the movement. the importance of the development of this study is that it has been seen that the "scare respirator" could avoid central apneas, but no studies have been done on the change in respiratory rate that occurs with the device or if it bothers the nb or alters its wakefulness sleep pattern. it is intended to evaluate 10 premature infants, during 3 observation periods. heart rate (hr), respiratory rate (rr) and saturation, pain scale and aeeg sleep wake pattern will be evaluated; first a rest period between feeds as baseline, then with a scare respirator at 20 cycles per minute and finally at 40 cycles per minute. the differences of qualitative and quantitative variables will be assessed with ad-hoc statistical tests.

Eligibility criteria:
inclusion criteria: * hospitalized healthy preterm babies, * weighing more than 1500g at the time of the study exclusion criteria: * babies receiving any respiratory support * carrier of any mayor malformation or genetic condition

Keywords: respiratory rate scare ventilator sleep wake cycle
quality of life in patients with multimetastatic melanoma currently in remission (qualm)

Conditions: Melanoma (Skin) Stage IV; Remission

Summary: few studies have been conducted on the quality of life of patients with stage iv melanoma. particularly, there is no data regarding the quality of life of patients with a multimetastatic melanoma currently in remission. then, the main objective of this study is to evaluate the quality of life from a point of view medico-psycho-social in patients with multimetastatic melanoma in remission for more than 6 months.

the cutaneous melanoma, (9th rank of all cancers), was until recently neglected and poorly known by the general public. the metastatic stages have dramatic rates of survival: 25% at 1 year and 2% at 5 years with a median of about 6.2 months. however, in the last ten years, the treatment of metastatic forms has undergone a real revolution. its high metastatic potential for a very low initial tumor mass, gives evidence of a great aggressiveness. the cutaneous melanoma is resistant to the main therapeutics (chemotherapy and radiotherapy). thanks to the emergence of immunotherapies and targeted therapies anti-raf (rapidly accelerated fibrosarcoma) and anti-mek (mitogen-activated extracellular) the prognosis of patients with metastatic melanoma has considerably improved, increasing the number of "long-term survivors". however, these treatments can cause many adverse effects that can impact patients' quality of life, despite a better tolerance compared to conventional chemotherapies. to our knowledge there are no data regarding the quality of life of patients with metastatic melanoma currently in remission.for this purpose, it is necessary to obtain solid data using validated questionnaires. thus, we have chosen to evaluate quality of life using specific questionnaires to better understand patients' expectations, their difficulties, and then to improve the relationship between the patient and the physician.

Eligibility criteria:
inclusion criteria: * adult patients * presenting a stage iv melanoma of the american joint committee on cancer (ajcc) classification (multimetastatic) in remission for more than 6 months: * complete remission (defined as the complete disappearance of target lesions according to the recist criteria, based on a thoraco-abdomino-pelvic ct scan and a brain magnetic resonance imaging (mri) or * complete metabolic remission (defined as the complete disappearance of target lesions in pet ct (positron emission tomography computed tomograph, that is to say, disappearance of the hypermetabolic character of the anatomic structures. there may remain target lesions in conventional ct but they are not hypermetabolic in pet ct) * patients able to answer the questionnaires * patients with enough understanding of the french language exclusion criteria: * adjuvant treatment * patient under tutorship or curatorship * refusal to participate in the study

Keywords: melanoma stage iv remission quality of life
an observational study of the functional capacity of heart failure

Conditions: Acute Heart Failure

Summary: this is an observational study of the functional capacity of patients with heart failure with reduced ejection fraction (hfref) who are admitted to the hospital for routine medical treatment.

this observational study will evaluate the functional capacity (ability to walk and distance walked) of patients with heart failure with reduced ejection fraction (hfref) in approximately 50-70 patients who present with acute heart failure to approximately 5-6 hospital sites in the usa. all enrolled patients will be evaluated for their baseline functional capacity. patients will receive standard acute heart failure therapy and will be serially assessed for change in their functional capacity.

Eligibility criteria:
inclusion criteria: * have a left ventricular ejection fraction (lvef) ≤40%, as assessed by any method, e.g., echocardiography, a multigated acquisition (muga) scan or magnetic resonance imaging (mri); * present with signs and symptoms considered to be primarily due to ahf and be admitted to the hospital for ahf; * confirmation verbally that the patient was ambulatory, i.e., able to walk \>30m, prior to developing symptoms of ahf leading to the current admission; * be capable of understanding the nature of the trial; be willing and able to comply with the inpatient and outpatient study protocol requirements for the duration of the study; and be willing to participate, as documented by written informed consent. exclusion criteria: * have a systolic blood pressure \ 170mmhg at baseline; * have an anticipated need for an invasive procedure within 3 days of study enrollment, e.g., due to hemodynamic or cardiac rhythm instability, or acute coronary syndrome, requiring procedures including, but not limited to, cardiac catheterization, placement of a defibrillator/pacemaker, or placement of a pulmonary artery catheter; * have a primary hf etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy (as defined by any wall thickness \> 1.8cm) that is obstructive, or uncorrected severe valvular disease (except mitral regurgitation); * have any other comorbidities that limit ambulation more than the patient's heart failure, e.g., symptomatic peripheral arterial disease, copd, arthritis or other condition, as confirmed verbally with the patient; * have severe renal insufficiency (defined as a gfr \<30ml/min/1.73m2 according to the mdrd equation); * have an anticipated survival of less than 90 days, for any reason; * have received an investigational agent (drug, device or biologic product) within 30 days (or, if longer, 5 half-lives for a drug or biologic agent) prior to study entry, or be planning to receive an investigational agent at any time throughout the full duration of the study until at least study day 35; * have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial.

Keywords: heart failure 6 minute walk test
validation of a historical physical activity survey

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to compare long-term recall of physical activity up to 15 years in the past with physical activity reports and physical fitness levels assessed at the baseline examination.

background: sedentary habits in middle-aged individuals are associated with increased risk for cardiovascular disease. studies examining this association typically have assessed physical activity participation in a narrow window, (for example, 1 week or 1 month) relative to probable disease etiology and progression. when the study was initiated, the possible relation of long-term physical activity patterns over decades or a lifetime to disease risk was not known because there existed no validated method of determining such exposure, but such studies were needed. it was hypothesized that validation of long-term recall of activity could lead to the application of lifetime physical activity patterns questionnaires. data on lifetime activity patterns might be useful in case-comparison and prospective studies of cardiovascular disease. design narrative: data analyzed for this project were from a cohort that had been under observation in the aerobics center longitudinal study. baseline preventive medical examinations were given to 6,902 men and women during the interval from 1971-1982. current physical activity and physical fitness levels (maximal exercise treadmill test) were assessed at baseline. participants also completed a lifetime physical activity pattern questionnaire as part of a mail survey done in 1986. self-reported physical activity from the 1986 questionnaire was used to categorize participants' physical activity levels for the years 1971-1985. these recalled levels of activity were compared to physical activity and physical fitness levels assessed during those same years at the baseline examinations (measure of truth). for example, participants who reported in the 1986 survey that they engaged in relatively high levels of physical activity in 1976 were expected to have recorded higher levels of physical fitness at the 1976 examination than participants who reported in 1986 that they were relatively sedentary in 1976. the study design permitted evaluation of how accurately participants recalled their physical activity up to 15 years in the past and allowed quantification of the errors investigators might expect from such assessments. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
lendormin d® tablet (drug use result survey)

Conditions: Sleep Initiation and Maintenance Disorders

Summary: study to investigate the safety and the efficacy in patients with insomnia, receiving lendormin d tablet under condition of normal clinical practice.


Eligibility criteria:
inclusion criteria: * patients with insomnia exclusion criteria: * none